Novo Holdings A/S’s MapLight Therapeutics MPLT Stock Holding History

Novo Holdings A/S’s Portfolio MPLT Stock Details MPLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$132M	Hold	3,686,622	–	–	7.67%	5
2026 Q1	$74.9M	Hold	3,686,622	–	–	6.07%	5
2025 Q4	$64.8M	Buy	+3,686,622	New	+$61.8M	5.03%	8

Other funds holding MPLT

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Novo Holdings A/S's MPLT Position: Q2 2026 in Review

Novo Holdings A/S held its MapLight Therapeutics (MPLT) position steady in Q2 2026 at 3,686,622 shares worth $132M. The position accounts for 7.67% of the portfolio, ranked #5.

Novo Holdings A/S first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 106 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

Novo Holdings A/S held 3,686,622 shares of MapLight Therapeutics worth $132M as of Q2 2026.
Novo Holdings A/S left its MapLight Therapeutics share count unchanged in Q2 2026.
MapLight Therapeutics made up 7.67% of Novo Holdings A/S's portfolio in Q2 2026, its #5 holding.
Novo Holdings A/S first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
106 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.